Cardinal Health Inc (NYSE:CAH) CEO Michael C. Kaufmann sold 18,586 shares of Cardinal Health stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $73.90, for a total transaction of $1,373,505.40. Following the completion of the sale, the chief executive officer now directly owns 211,849 shares of the company’s stock, valued at approximately $15,655,641.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Cardinal Health Inc (NYSE CAH) traded down $0.30 during trading on Tuesday, hitting $73.21. 2,217,052 shares of the stock traded hands, compared to its average volume of 3,170,000. The stock has a market cap of $23,080.00, a PE ratio of 21.34, a PEG ratio of 1.65 and a beta of 0.85. Cardinal Health Inc has a 1-year low of $54.66 and a 1-year high of $84.88. The company has a quick ratio of 0.52, a current ratio of 1.06 and a debt-to-equity ratio of 1.35.
Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.00 by $0.09. The business had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $33.48 billion. Cardinal Health had a net margin of 0.84% and a return on equity of 25.24%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.24 EPS. equities research analysts expect that Cardinal Health Inc will post 5.12 EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of CAH. Macquarie Group Ltd. lifted its stake in shares of Cardinal Health by 4.6% during the 3rd quarter. Macquarie Group Ltd. now owns 10,105,374 shares of the company’s stock valued at $676,253,000 after buying an additional 445,399 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Cardinal Health by 38.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 4,930,457 shares of the company’s stock valued at $329,964,000 after buying an additional 1,373,334 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Cardinal Health by 10.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,846,209 shares of the company’s stock valued at $257,388,000 after buying an additional 375,742 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Cardinal Health by 58.7% during the 3rd quarter. American Century Companies Inc. now owns 2,976,776 shares of the company’s stock valued at $199,206,000 after buying an additional 1,100,507 shares in the last quarter. Finally, Boston Partners lifted its stake in shares of Cardinal Health by 31.0% during the 3rd quarter. Boston Partners now owns 2,918,367 shares of the company’s stock valued at $195,297,000 after buying an additional 690,827 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.
A number of equities research analysts have commented on the stock. Evercore ISI assumed coverage on shares of Cardinal Health in a research report on Thursday, January 4th. They issued an “in-line” rating and a $67.00 target price for the company. Zacks Investment Research raised shares of Cardinal Health from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardinal Health in a research report on Thursday, October 12th. Cowen raised shares of Cardinal Health to a “buy” rating and set a $74.00 target price for the company in a research report on Tuesday, October 10th. Finally, Mizuho set a $70.00 target price on shares of Cardinal Health and gave the stock a “hold” rating in a research report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the company. Cardinal Health presently has an average rating of “Hold” and a consensus target price of $73.58.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/23/cardinal-health-inc-cah-ceo-michael-c-kaufmann-sells-18586-shares.html.
Cardinal Health Company Profile
Cardinal Health, Inc is a healthcare services and products company. The Company operates through two segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products. This segment also operates nuclear pharmacies and cyclotron facilities; provides pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, and provides services to healthcare companies.
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.